Silexion Therapeutics Corp Logo

Silexion Therapeutics Corp

Developing a local drug delivery platform to treat KRAS-driven cancers and solid tumors.

SLXN | US

Overview

Corporate Details

ISIN(s):
KYG1281K1141 (+1 more)
LEI:
Country:
United States of America
Address:
12 ABBA HILLEL ROAD, 5250606 RAMAT GAN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers and other solid tumors, such as pancreatic cancer. The company's core technology is its proprietary LODER (Local Drug Eluter) drug delivery platform. This platform is designed to provide local and prolonged delivery of therapeutic agents directly within the tumor core, aiming to solve significant drug delivery challenges and improve outcomes for patients with hard-to-treat cancers. Silexion is also developing innovative RNA-based therapeutics and collaborates with industry partners to advance its clinical manufacturing and formulation development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Silexion Therapeutics Corp filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Silexion Therapeutics Corp

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Silexion Therapeutics Corp via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

GH Research PLC Logo
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America
GHRS
GI Innovation Inc. Logo
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea
358570
GILEAD SCIENCES, INC. Logo
Develops innovative medicines for life-threatening diseases in virology, oncology & inflammation.
United States of America
GILD
GlaxoSmithKline PLC Logo
A biopharmaceutical company developing vaccines and specialty medicines to prevent and treat disease.
United Kingdom
GSK
GL Pharm Tech Corp. Logo
Develops improved drugs and generics, and licenses proprietary drug formulation technologies.
South Korea
204840
GNI  Group Ltd. Logo
Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.
Japan
2160
Goodwill Pharma Plc Logo
Integrated pharma CDMO developing Rx/OTC meds, supplements & devices for CEE markets.
Hungary
GWPH
Gossamer Bio, Inc. Logo
Clinical-stage biopharma developing inhaled therapies for rare pulmonary hypertension.
United States of America
GOSS
Grace Therapeutics, Inc. Logo
Develops improved drugs for rare neurological diseases using novel drug delivery technologies.
United States of America
GRCE
A biotech firm in biopharma, diagnostics, digital health, and consumer wellness products.
South Korea
005250

Talk to a Data Expert

Have a question? We'll get back to you promptly.